Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post by Razelle Kurzrock, Founding Director of Michels Rare Cancers Research Laboratories at the Medical College of Wisconsin and Co-Founder and Board Member at CureMatch, adding:
“Sharing our comment just published on The Lancet Oncology “Factors that can make overall survival unreliable as a clinical trial outcome.”
Quoting Razelle Kurzrock‘s post:
“Our commentary. Very important.”
Title: Factors that can make overall survival unreliable as a clinical trial outcome
Authors: David J. Stewart, Vivek Subbiah, Mathew Vogel, Tim Ramsay, Razelle Kurzrock
Read the Full Article.
More posts featuring Vivek Subbiah and Razelle Kurzrock on OncoDaily.